Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma.
Phase of Trial: Phase I/II
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Bevacizumab (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Dec 2016 Phase II portion of this trial was discontinued according to results published in the Targeted Oncology.
- 09 Dec 2016 Results published in the Targeted Oncology
- 07 Feb 2013 New source identified and integrated (Mayo Clinic record, 08-007502).